Loading
A phase 1/2 trial of Acalabrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia is a phase 1/2 interventional study registered as NCT02029443 by Acerta Pharma BV, with 306 participants enrolled, started 2014-01-30 and due to reach its primary completion in 2021-07-15. Interventions recorded: Acalabrutinib. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
306 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2022-09-10), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) in Phase 1primary | Cohort 1 | 9 | 0 participants | - | - | link |
| Cohort 2a | 8 | 0 participants | ||||
| Cohort 2b | 29 | 0 participants | ||||
| Cohort 3 | 7 | 0 participants | ||||
| Cohort 4a | 6 | 0 participants | ||||
| Cohort 4b | 6 | 0 participants |
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia and the tag pipeline.